News

Avammune Therapeutics raises $12 million to advance cancer therapies

Publications

Small molecule innate immune modulators in cancer therapy
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb, Aditya Kulkarni

PMID: 39318624 PMCID: PMC11419979 DOI:10.3389/fimmu.2024.1395655

AVA-ADR-001 Suppresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150
Aditya Kulkarni, Avijit Goswami, Barnali Deb, Ankita Mohanty, Sandeep Goyal, Kawaljit Singh, Rahul Yadav, Princy Khurana, Narenkumar Muralidharan, Jan Rehwinkel

Molecules 2022,27(19), 6721; DOI: 10.3390/molecules27196721

Conference Abstracts

Abstract 6898: Identification of a novel first-in-class inhibitor targeting the ADAR1 p150 isoform demonstrates robust anti-tumor efficacy in a syngeneic mouse model
Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Aditya Kulkarni

Journal: Cancer Research Cancer Res (2025) 85 (8_Supplement_1): 6898. https://doi.org/10.1158/1538-7445.AM2025-6898

Abstract 652: Exploring the therapeutic benefit of AVA-NP-695 with combination modalities in ICB refractory and rare cancers
Borja Ruiz-Fernandez de Cordoba, Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Alejandro Sweet-Cordero, Aditya Kulkarni

Journal: Cancer Research Cancer Res (2025) 85 (8_Supplement_1): 652. https://doi.org/10.1158/1538-7445.AM2025-652

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics